Dipyridamole SR Pellets Manufacturer in India

Swapnroop Pharma · WHO-GMP Certified · +91 87670 62101

Dipyridamole SR Pellets

Dipyridamole SR Pellets are pharmaceutical-grade sustained-release multiparticulate pellets containing Dipyridamole as the active pharmaceutical ingredient. The pellet system is designed for oral formulations where a controlled and prolonged release profile is required.

Dipyridamole has CAS Number 58-32-2, molecular formula C₂₄H₄₀N₈O₄, and molecular weight 504.63 g/mol. The current USP-NF monograph specifies Dipyridamole at 98.0%–102.0% on a dried basis. This is an API specification and should not be transferred directly to the finished SR pellet assay.

In a sustained-release pellet formulation, Dipyridamole is incorporated into individual pellet units and the release profile is controlled through the pellet composition and/or release-controlling coating system. Important formulation variables can include pellet size, active loading, polymer type, polymer concentration, coating weight gain, coating thickness and coating uniformity.

Commercial pharmaceutical pellet references specifically report Dipyridamole SR Pellets at 40% w/w. One commercial product also lists Dipyridamole SR 40% + Aspirin IR 51% w/w as a combination pellet system. Another current commercial portfolio lists Dipyridamole SR Pellets 40% w/w.

For the SDP product page, 40% w/w should be displayed as an available strength only if it matches the current SDP product specification or COA.

Pharmaceutical-Grade Dipyridamole SR Pellets

Dipyridamole SR Pellets provide a multiparticulate platform for sustained-release oral formulation development. Individual pellet units can provide flexibility in controlling active loading, pellet size, coating characteristics and release performance.

The finished pellets can be evaluated for assay, content uniformity, particle-size distribution, moisture, bulk density, tapped density, friability, pellet morphology and sustained-release dissolution.

The release profile is formulation-specific. Therefore, a universal dissolution percentage or time-point should not be published without the actual validated SDP finished-product specification.

Dipyridamole Sustained-Release Pellets for Oral Formulations

Dipyridamole SR Pellets can be considered for:

  • Sustained-release oral formulations
  • Multiparticulate formulations
  • Capsule-filling applications
  • Controlled-release formulation development
  • Functional-coated pellet systems
  • Pharmaceutical formulation research
  • Process development and scale-up
  • Bulk pharmaceutical formulation requirements

Pellet Quality Characteristics

Important finished-product quality attributes include:

  • Active ingredient loading
  • HPLC assay
  • Content uniformity
  • Particle-size distribution
  • Moisture / LOD
  • Bulk density
  • Tapped density
  • Friability
  • Sphericity
  • Pellet morphology
  • Coating weight gain
  • Coating uniformity
  • Sustained-release dissolution

These parameters should be controlled according to the specific finished-product specification.

Detailed Specifications

Parameter Specification
Appearance white to off-white crystalline powder
Identification IR & HPLC compliant
Assay (HPLC) 98.0% – 102.0%
Loss on Drying NMT 1.0%
Residue on Ignition NMT 0.1%
Individual Impurity NMT 0.5%
Water Content NMT 1.0%
Get Bulk Quote via WhatsApp